Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro™ (tirzepatide) injection Right
  4. Can Mounjaro™ (tirzepatide) be used in children?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro™ (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can Mounjaro™ (tirzepatide) be used in children?

Tirzepatide’s safety and efficacy have not been established in patients under 18 years. SURPASS-PEDS is evaluating tirzepatide in patients 10 to below 18 years old with type 2 diabetes inadequately controlled with metformin, basal insulin, or both.

US_cFAQ_TZP073_PEDIATRIC_ADOLESCENT_POPULATION
US_cFAQ_TZP073_PEDIATRIC_ADOLESCENT_POPULATION
en-US

See important safety information, including boxed warning, in the attached prescribing information.

Approved Indication

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1

Use in Children

The safety and efficacy of tirzepatide have not been established in pediatric patients and tirzepatide is not approved for use in patients younger than 18 years.

SURPASS-PEDS is an ongoing, phase 3, randomized, double-blind study with an open-label extension, evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of once-weekly tirzepatide compared with placebo in pediatric and adolescent patients with T2D. The study duration is approximately 60 weeks.2

The primary outcome is change from baseline in glycated hemoglobin (HbA1c) at week 30. Key inclusion criteria are 

  • participants aged 10 to below 18 years at screening
  • T2D
  • treatment with diet and exercise and metformin and/or basal insulin at stable doses for at least 90 days
  • HbA1c >6.5% to ≤11% at screening, and
  • body weight ≥110 pounds (50 kg) and body mass index >85th percentile.2

Enclosed Prescribing Information

MOUNJARO™ (tirzepatide) injection, for subcutaneous use, Lilly

References

1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

2A study to evaluate tirzepatide (LY3298176) in pediatric and adolescent participants with type 2 diabetes mellitus inadequately controlled with metformin or basal insulin or both (SURPASS-PEDS). ClinicalTrials.gov identifier: NCT05260021. Updated February 23, 2023. Accessed March 1, 2023. https://clinicaltrials.gov/ct2/show/NCT05260021

Date of Last Review: February 14, 2023

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly